ty -jour t1-苯二氮卓受体拮抗剂（flumazenil）不影响与睡眠相关的呼吸障碍JF -Europen呼吸杂志JO -EUR RESSIR J SP -1816 LP -1816 LP -1820 VL -1820 VL -9 IS -9 AU -9 AU -Schonhofer，Schonhofer，BAU -KOHLER，BAU -KOHLER，BAU -KOHLER，BAU -KOHLER，BAID Y1-1996/09/01 UR -http：//www.qdcxjkg.com/content/9/9/9/1816.Abstract N2-苯二氮卓类药物可能会损害睡眠期间的呼吸，从而导致睡眠呼吸呼吸的发展或在患有睡眠呼吸暂停的受试者中，预先存在的呼吸暂停的严重程度增加。Flumazenil是一位选择性的苯二氮卓类抗逆邦剂。我们假设苯二氮卓受体的内源配体可能有助于阻塞性睡眠呼吸暂停综合征（OSA）的发病机理，因此，氟马西尼可以降低OSA的强度。研究了10名男性患者（平均年龄55岁，平均体重指数42.4 kg.m-2，平均呼吸暂停指数（AI）53.5和平均呼吸障碍指数（RDI）74.2）。在研究之前，没有患者接受过OSA的治疗。研究设计是随机的，单盲的，安慰剂对照和交叉的。在第一个或第二个学习之夜，将患者随机分配接受静脉注射。flumazenil（2 mg）或安慰剂（0.9％NaCl）在01:00至01:30 h之间。 Comparing the polysomnographic results of the placebo night and the flumazenil night in all 10 patients, no significant differences were found regarding obstructive events or sleep architecture. Accordingly, the data concerning sleep-disordered breathing and sleep stages during the 30 min period prior to and the 30 min period following the administration of flumazenil did not differ. It is concluded that endogenous ligands of the benzodiazepine receptor play no role in the pathogenesis of obstructive sleep apnoea syndrome, since respiratory and sleep data are not altered by flumazenil. Therefore, attempts to treat obstructive sleep apnoea syndrome with flumazenil do not seem to be warranted. ER -